Neogenomics (NEO) Operating Leases (2019 - 2026)

Neogenomics (NEO) has reported Operating Leases for 8 consecutive years, with $61.5 million the latest figure, recorded in Q1 2026.

• Operating Leases for Q1 2026 came in at $61.5 million, up 2.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $61.5 million (up 2.67% YoY), and the FY2025 annual result was $62.8 million, up 3.26% from the prior year.
• Operating Leases was $61.5 million for Q1 2026 at Neogenomics, down from $62.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $73.4 million in Q1 2022 and troughed at $59.9 million in Q1 2025.
• Average Operating Leases over 5 years is $65.5 million, with a median of $64.8 million recorded in 2024.
• Year-over-year, Operating Leases jumped 44.85% in 2022 and fell 12.01% in 2023.
• Over 5 years, Operating Leases stood at $69.0 million in 2022, then dropped by 1.57% to $67.9 million in 2023, then declined by 10.36% to $60.8 million in 2024, then advanced by 3.26% to $62.8 million in 2025, then dropped by 2.17% to $61.5 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $61.5 million in Q1 2026, $62.8 million in Q4 2025, and $64.3 million in Q3 2025.